BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $73 | -90.3% | 364 | 0.0% | 0.00% | – |
| Q2 2023 | $750 | -37.6% | 364 | 0.0% | 0.00% | – |
| Q1 2023 | $1,201 | +101.2% | 364 | 0.0% | 0.00% | – |
| Q4 2022 | $597 | -100.0% | 364 | 0.0% | 0.00% | – |
| Q3 2022 | $1,609,000 | +60.1% | 364 | 0.0% | 0.00% | – |
| Q2 2022 | $1,005,000 | -37.8% | 364 | -24.3% | 0.00% | – |
| Q1 2022 | $1,616,000 | -16.0% | 481 | 0.0% | 0.00% | – |
| Q4 2021 | $1,924,000 | +21.2% | 481 | 0.0% | 0.00% | – |
| Q3 2021 | $1,587,000 | -78.0% | 481 | -74.7% | 0.00% | – |
| Q2 2021 | $7,228,000 | -53.7% | 1,902 | -53.4% | 0.00% | – |
| Q1 2021 | $15,626,000 | -43.5% | 4,080 | -33.3% | 0.00% | – |
| Q4 2020 | $27,679,000 | -75.5% | 6,117 | -8.5% | 0.00% | – |
| Q3 2020 | $113,144,000 | +910.3% | 6,687 | +569.4% | 0.00% | – |
| Q2 2020 | $11,199,000 | – | 999 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 239,000 | $2,679,000 | 0.48% |
| EAM Investors, LLC | 81,854 | $918,000 | 0.20% |
| CFO4Life Group, LLC | 12,003 | $135,000 | 0.05% |
| Phoenix Holdings Ltd. | 104,782 | $1,112,000 | 0.05% |
| WINTON GROUP Ltd | 118,487 | $1,328,000 | 0.03% |
| Merit Financial Group, LLC | 28,731 | $322,000 | 0.03% |
| HighPoint Advisor Group LLC | 13,533 | $151,000 | 0.03% |
| SHANDA ASSET MANAGEMENT HOLDINGS Ltd | 23,000 | $258,000 | 0.02% |
| ETF MANAGERS GROUP, LLC | 52,216 | $579,000 | 0.02% |
| IHT Wealth Management, LLC | 13,000 | $146,000 | 0.02% |